Prognostic Values of VEGF and Endostatin with Malignant Pleural Effusions in Patients with Lung Cancer

Yu, Li; Lu, Gui-Fu; Xia, Ning; Xie, Hai‐Yan; Hu, Wei; Hao, Ke-Ke; Xu, Chunhua; Qian, Qian

doi:10.7314/apjcp.2014.15.19.8435

Cited by 16 publications

(12 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…VEGF can be released by both malignant and inflammatory cells, and various studies indicated that VEGF is associated with Regulation mechanism of three high confident target genes and miRNAs, and related biological functions survival and pleurodesis outcomes in MPE [6,13]. Both VEGF and HSP90B1 are critical in the development of MPE by regulating angiogenesis [36]. VEGF has also been used as drug target of Bevacizumab and Cisplatin for the treatment of MPE in advanced stage non-smallcell lung cancer from one clinical trial by Chinese PLA General Hospital (NCT01661790).…”

Section: Discussionmentioning

confidence: 99%

Identification of differentially expressed miRNAs in differentiating benign from malignant pleural effusion

Bao

Ding

et al. 2020

Hereditas

View full text Add to dashboard Cite

Background: Tuberculosis pleural effusion (TPE) and malignant pleural effusion (MPE) are very common clinical complications. Considering the totally different prognosis and clinical treatment of TPE and MPE, the accurate and noninvasive diagnosis are very critical for patients with pleural effusion to initiate efficient management and treatment. However, effective clinical biomarkers were rarely explored to distinguish benign from MPE. The purpose of this study is to identify potential miRNAs which can probably be used to differentiate malignant pleural effusion from TPE. Results: A total of 23 significantly differentially expressed miRNAs were identified in MPE, with 18 up-expressed and 5 down-expressed. And the target genes of the miRNAs mainly involved in the biology process of nervous system, cancer, immune system and metabolic process etc. Three high confident target genes, AGO4, FGF9 and LEF1 can be regulated by miR-195-5p, miR-182-5p and miR-34a-5p respectively. And these genes participate in the canonical pathway of regulation of the Epithelial-Mesenchymal and the biological functions of apoptosis, growth of tumor and cell proliferation of tumor cell lines. Further, RT-PCR validation results based on 64 collected individuals showed that the expression levels of the three miRNAs were 2-5 times higher in MPE samples, which were consistent with the microarray results. In addition, ROC curve analysis demonstrated that the combination of the three miRNAs can achieve higher AUC of 0.93 (p-value< 0.0001) to differentiate MPE from TPE. Conclusions: The identified miR-195-5p, miR-182-5p and miR-34a-5p can become potential diagnostic biomarkers for MPE with further evidences.

show abstract

Section: Discussionmentioning

confidence: 99%

Identification of differentially expressed miRNAs in differentiating benign from malignant pleural effusion

Bao

Ding

et al. 2020

Hereditas

View full text Add to dashboard Cite

show abstract

“…Besides, the activated receptor ERBB4 can also affect glycoprotein PDPN to trigger TFs, GATA3 and FOXO3 through cascade proteins CHIC2, Moesin (MSN), TUBB3, RHOXF2, SMG1 in the signaling pathways, to regulate proliferation through the mediation of FOXO3 , SMG1 , and NF1 , to regulate cell mobility through the mediation of NF1 , to regulate cell adhesion through the mediation of CDH3 , and to regulate lymphangiogenesis through the mediation of VEGFC (Figure 6F). COL18A1 encodes Type XVIII collagen, also known as Endostatin, a potent antiangiogenic protein that is able to inhibit angiogenesis and is associated with malignant pleural effusions in patients of lung cancer [164, 165]. Besides, COL18A1 is a regulator of the oxidative stress response and has been suggested that the potential links between ECM and oxidative stress response in cancer.…”

Section: Discussionmentioning

confidence: 99%

Comparing progression molecular mechanisms between lung adenocarcinoma and lung squamous cell carcinoma based on genetic and epigenetic networks: big data mining and genome-wide systems identification

Yeh

Chang

et al. 2019

Oncotarget

View full text Add to dashboard Cite

Non-small-cell lung cancer (NSCLC) is the predominant type of lung cancer in the world. Lung adenocarcinoma (LADC) and lung squamous cell carcinoma (LSCC) are subtypes of NSCLC. We usually regard them as different disease due to their unique molecular characteristics, distinct cells of origin and dissimilar clinical response. However, the differences of genetic and epigenetic progression mechanism between LADC and LSCC are complicated to analyze. Therefore, we applied systems biology approaches and big databases mining to construct genetic and epigenetic networks (GENs) with next-generation sequencing data of LADC and LSCC. In order to obtain the real GENs, system identification and system order detection are conducted on gene regulatory networks (GRNs) and protein-protein interaction networks (PPINs) for each stage of LADC and LSCC. The core GENs were extracted via principal network projection (PNP). Based on the ranking of projection values, we got the core pathways in respect of KEGG pathway. Compared with the core pathways, we found significant differences between microenvironments, dysregulations of miRNAs, epigenetic modifications on certain signaling transduction proteins and target genes in each stage of LADC and LSCC. Finally, we proposed six genetic and epigenetic multiple-molecule drugs to target essential biomarkers in each progression stage of LADC and LSCC, respectively.

show abstract

“…This was particularly impressive in the subset of patients with non-squamous histology. Bevacizumab is generally well tolerated and does not appear to increase the incidence or severity of nausea/vomiting, neuropathy and renal toxicity, which are typically associated with carboplatin/paclitaxel chemotherapy ( 74 , 88 – 91 ). Nevertheless, although bevacizumab improves outcomes when added to platinum-based chemotherapy in advanced-stage non-squamous NSCLC, a recent phase III trial study demonstrated that the addition of bevacizumab to adjuvant chemotherapy did not improve overall survival for patients with surgically resected early-stage NSCLC ( 92 ).…”

Section: Vegf In the Prognosis Of Mpe In Various Subtypes Of Nsclc Anmentioning

confidence: 99%

The role of VEGF in the diagnosis and treatment of malignant pleural effusion in patients with non‑small cell lung cancer (Review)

Yao

Mathy

2018

Mol Med Report

View full text Add to dashboard Cite

Malignant pleural effusion (MPE) is a severe medical condition, which can result in breathlessness, pain, cachexia and reduced physical activity. It can occur in almost all types of malignant tumors; however, lung cancer is the most common cause of MPE, accounting for ~1/3 of clinical cases. Although there are numerous therapeutic approaches currently available for the treatment of MPE, none are fully effective and the majority can only alleviate the symptoms of the patients. Vascular endothelial growth factor (VEGF) has now been recognized as one of the most important regulatory factors in tumor angiogenesis, which participates in the entire process of tumor growth through its function to stimulate tumor angiogenesis, activate host vascular endothelial cells and promote malignant proliferation. Novel drugs targeting VEGF, including endostar and bevacizumab, have been developed and approved for the treatment of various tumors. Data from recent clinical studies have demonstrated that drugs targeting VEGF are effective and safe for the clinical management of MPE. Therefore, VEGF-targeting represents a promising novel strategy for the diagnosis and treatment of MPE. The present review summarized recent advances in the role of VEGF in the pathogenesis, diagnosis and clinical management of MPE in patients with non-small cell lung cancer.

show abstract

Prognostic Values of VEGF and Endostatin with Malignant Pleural Effusions in Patients with Lung Cancer

Cited by 16 publications

References 32 publications

Identification of differentially expressed miRNAs in differentiating benign from malignant pleural effusion

Identification of differentially expressed miRNAs in differentiating benign from malignant pleural effusion

Comparing progression molecular mechanisms between lung adenocarcinoma and lung squamous cell carcinoma based on genetic and epigenetic networks: big data mining and genome-wide systems identification

The role of VEGF in the diagnosis and treatment of malignant pleural effusion in patients with non‑small cell lung cancer (Review)

Contact Info

Product

Resources

About